BioCentury | May 25, 2009
Finance

Ebb & Flow

In just six years, Cougar Biotechnology Inc. (NASDAQ:CGRB) has managed to turn a Phase I prostate cancer candidate, a reverse merger and $138 million into a $1 billion acquisition by Johnson & Johnson (NYSE:JNJ). The...
BioCentury | May 4, 2009
Product Development

Opportunity in Crisis

...vaccines, several companies are working on adjuvants alone. Hemispherx Biopharma Inc. is collaborating with Japan's National Institute of Infectious Diseases (NIID)...
...Clinic , Roche ster, Minn. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md. National Institute of Infectious Diseases (NIID)...
Items per page:
1 - 2 of 2
BioCentury | May 25, 2009
Finance

Ebb & Flow

In just six years, Cougar Biotechnology Inc. (NASDAQ:CGRB) has managed to turn a Phase I prostate cancer candidate, a reverse merger and $138 million into a $1 billion acquisition by Johnson & Johnson (NYSE:JNJ). The...
BioCentury | May 4, 2009
Product Development

Opportunity in Crisis

...vaccines, several companies are working on adjuvants alone. Hemispherx Biopharma Inc. is collaborating with Japan's National Institute of Infectious Diseases (NIID)...
...Clinic , Roche ster, Minn. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md. National Institute of Infectious Diseases (NIID)...
Items per page:
1 - 2 of 2